Search
Displaying 981–990 of 1066 results
-
VISIONS 2015 — Dr. Shannon Boye Receives FFB Award for Excellence in Gene-Therapy Research
Research NewsDr. Boye received the Foundation’s Board of Director’s Award, which was presented at VISIONS 2015, FFB’s annual conference, for achievements in retinal research.
-
ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research
Research NewsThe mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases.
-
ARVO 2015 Highlight: New Research Boosts Prospects for Saving Vision with RdCVF
Research NewsAfter years of refinement and testing in animal models, the emerging therapy is about a year and a half from moving into a clinical trial.
-
ARVO 2015 Highlight: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes
Research NewsOne of the hot topics at ARVO this year is a rapidly advancing gene-therapy approach called clustered regularly interspaced short palindromic repeats, or CRISPR.
-
Beacon Stories
An interview with Louis Posen, record label founder and retinitis pigmentosa patient.
-
Need-to-Know Information about Clinical Trials
Research NewsA primer on what you can expect from clinical trials.
-
Beacon Stories
People with retinal disease describe their experiences “not looking blind.”
-
CME — What It Is, and Why People with Retinal Diseases Should Know About It
Research NewsDr. Gerald Fishman discusses cystoid macular edema (CME), a potentially damaging accumulation of fluid in the retina affecting up to 32 percent of people with retinitis pigmentosa (RP).
-
A Stem-Cells Video for Kids (and Newbies of All Ages)
Research NewsBiology and genetics can be difficult to understand for even an educated adult, so when something kid-friendly is produced, especially a video, we are eager to share it.
-
Low-Hanging Fruit: Repurposing Drugs to Treat Retinal Diseases
Research NewsBecause repurposing relies on prior research and clinical data, it reduces the cost and time needed to establish a new therapeutic application for the drug.
